HTL 18318

Drug Profile

HTL 18318

Alternative Names: HTL 0018318; HTL18318

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Class Antidementias; Antipsychotics; Nootropics; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 07 Apr 2016 HTL 18318 licensed to Allergan Pharmaceuticals worldwide
  • 21 Mar 2016 Heptares Therapeutics initiates a phase I trial Cognition disorders (In volunteers) in Netherlands (PO, Liquid) (NTR5781)
  • 10 Feb 2016 Phase-I clinical trials in Cognition disorders (In volunteers) in United Kingdom (PO, Liquid) (9191164; NCT02958696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top